SG11202009295YA - Treatment and prophylaxis of amyloidosis - Google Patents

Treatment and prophylaxis of amyloidosis

Info

Publication number
SG11202009295YA
SG11202009295YA SG11202009295YA SG11202009295YA SG11202009295YA SG 11202009295Y A SG11202009295Y A SG 11202009295YA SG 11202009295Y A SG11202009295Y A SG 11202009295YA SG 11202009295Y A SG11202009295Y A SG 11202009295YA SG 11202009295Y A SG11202009295Y A SG 11202009295YA
Authority
SG
Singapore
Prior art keywords
amyloidosis
prophylaxis
treatment
Prior art date
Application number
SG11202009295YA
Other languages
English (en)
Inventor
Tarlochan Nijjar
Iii Philip J Dolan
Robin Barbour
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of SG11202009295YA publication Critical patent/SG11202009295YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202009295YA 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis SG11202009295YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647341P 2018-03-23 2018-03-23
PCT/US2019/023528 WO2019183448A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Publications (1)

Publication Number Publication Date
SG11202009295YA true SG11202009295YA (en) 2020-10-29

Family

ID=66041747

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009295YA SG11202009295YA (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Country Status (13)

Country Link
US (1) US20210017278A1 (https=)
EP (1) EP3768311A1 (https=)
JP (1) JP7217287B2 (https=)
KR (1) KR20200143400A (https=)
CN (1) CN112040983A (https=)
AU (2) AU2019240413A1 (https=)
BR (1) BR112020019172A2 (https=)
CA (1) CA3095100A1 (https=)
EA (1) EA202092264A1 (https=)
MX (1) MX2020009920A (https=)
MY (1) MY203432A (https=)
SG (1) SG11202009295YA (https=)
WO (1) WO2019183448A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2237803T3 (en) * 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
SG10201604104PA (en) * 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Also Published As

Publication number Publication date
EP3768311A1 (en) 2021-01-27
MY203432A (en) 2024-06-27
CN112040983A (zh) 2020-12-04
CA3095100A1 (en) 2019-09-26
BR112020019172A2 (pt) 2021-01-26
KR20200143400A (ko) 2020-12-23
AU2023202109A1 (en) 2023-05-18
EA202092264A1 (ru) 2020-12-03
JP7217287B2 (ja) 2023-02-02
WO2019183448A1 (en) 2019-09-26
AU2019240413A1 (en) 2020-10-08
MX2020009920A (es) 2020-12-10
US20210017278A1 (en) 2021-01-21
JP2021518393A (ja) 2021-08-02

Similar Documents

Publication Publication Date Title
SG10202101986UA (en) Tetracycline compounds and methods of treatment
GB201804514D0 (en) Treatment of pyroptosis
SG11202103033WA (en) Compositions and methods for the treatment of presbyopia
ZA202103977B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL276135A (en) Preparations and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
GB2596661B (en) Therapeutic and prophylactic use of microorganisms
IL278978A (en) Preparations and methods for treating eczema
ZA201903795B (en) Treatment of water
GB201804515D0 (en) Treatment of necroptosis
SG11202109097UA (en) Materials and methods for enhanced treatment and prevention of biofilms
IL290983A (en) Treatment methods
GB201916428D0 (en) Treatment of hydro-carbon-contaminated materials
GB201907305D0 (en) Treatment of conditions
IL276905A (en) Treatment and prevention of preeclampsia
GB201918853D0 (en) Methods of treatment
PT3781172T (pt) Tratamento da pneumonia
GB201810923D0 (en) Compositions and method of treatment
SG11202009295YA (en) Treatment and prophylaxis of amyloidosis
GB2590245B (en) Encapsulated antimicrobials and related methods of treatment
HK40051916A (zh) 淀粉样变性的治疗和预防
GB201912490D0 (en) Treatment of obesity and related conditions
GB201710491D0 (en) Composition and methods of treatment
GB201815000D0 (en) Treatment of hypothroidism and related conditions
GB201810925D0 (en) Compositions and methods of treatment